Product information and disease descriptionProduct description
Phase of product development
35 evidence topics · 23 sources
Regulatory status: Under review; BLA submitted September 2026 under the accelerated approval pathway, with a PDUFA target action date in May 2027
Launch
No evidence found.
Commercial launch preparation
FDA acceptance of the BLA with Priority Review, November 2026
BLA submission in August 2026 and acceptance in October 2026: Form 10-Q statement
Advisory committee meeting tentatively planned
Confirmatory study: alignment with the FDA on key design elements, November 2026
BLA submission and priority review request, September 2026
Type B meeting minutes, July 2026
Type B meeting, June 2026
BLA submission timing: third quarter of 2026, June 2026, superseded in September 2026
FDA position after the January 2026 Type A meeting, March 2026, superseded in June 2026
Type A meeting scheduled, January 2026
Pre-BLA meeting minutes, December 2025
BLA submission timing: unclear, November 2025, superseded in June 2026
BLA submission timing: first quarter of 2026, June 2025, superseded in November 2025
U.S. launch timing: 2026, September 2025, superseded in November 2025
FDA interactions on the statistical analysis plan, 2025
FDA interactions on chemistry, manufacturing and controls, 2025
FDA alignment on the accelerated approval pathway, December 2024, superseded in November 2025
Designations held: current statement
Regenerative Medicine Advanced Therapy designation: May 2024
Orphan drug designation: FDA, September 2017
| Field | Quoted record |
|---|---|
| Generic name | “adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene” |
| Date designated | “09/27/2017” |
| Orphan designation | “Treatment of Huntington's disease” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “uniQure Biopharma B.V.” |
Orphan designation: European Commission, January 2018
PRIority MEdicines (PRIME) designation
No evidence found.